211 related articles for article (PubMed ID: 7707419)
1. Molecular characterization of defective antigen processing in human prostate cancer.
Sanda MG; Restifo NP; Walsh JC; Kawakami Y; Nelson WG; Pardoll DM; Simons JW
J Natl Cancer Inst; 1995 Feb; 87(4):280-5. PubMed ID: 7707419
[TBL] [Abstract][Full Text] [Related]
2. Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC.
Neeley YC; McDonagh KT; Overwijk WW; Restifo NP; Sanda MG
Prostate; 2002 Nov; 53(3):183-91. PubMed ID: 12386918
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of the MHC class I antigen-processing machinery after oncogenic transformation of murine fibroblasts.
Seliger B; Harders C; Lohmann S; Momburg F; Urlinger S; Tampé R; Huber C
Eur J Immunol; 1998 Jan; 28(1):122-33. PubMed ID: 9485192
[TBL] [Abstract][Full Text] [Related]
4. Immune selection in murine tumors. Ph.d thesis.
Svane IM; Engel AM
APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
[TBL] [Abstract][Full Text] [Related]
5. MHC class I and II expression in prostate carcinoma and modulation by interferon-alpha and -gamma.
Bander NH; Yao D; Liu H; Chen YT; Steiner M; Zuccaro W; Moy P
Prostate; 1997 Dec; 33(4):233-9. PubMed ID: 9397194
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the major histocompatibility complex class I antigen presentation machinery in normal and malignant renal cells: evidence for deficiencies associated with transformation and progression.
Seliger B; Hohne A; Knuth A; Bernhard H; Meyer T; Tampe R; Momburg F; Huber C
Cancer Res; 1996 Apr; 56(8):1756-60. PubMed ID: 8620489
[TBL] [Abstract][Full Text] [Related]
7. Deficient expression of components of the MHC class I antigen processing machinery in human cervical carcinoma.
Ritz U; Momburg F; Pilch H; Huber C; Maeurer MJ; Seliger B
Int J Oncol; 2001 Dec; 19(6):1211-20. PubMed ID: 11713591
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the MHC class I antigen presentation machinery in human embryonal carcinomas: evidence for deficiencies in TAP, LMP and MHC class I expression and their upregulation by IFN-gamma.
Seliger B; Dunn T; Schwenzer A; Casper J; Huber C; Schmoll HJ
Scand J Immunol; 1997 Dec; 46(6):625-32. PubMed ID: 9420627
[TBL] [Abstract][Full Text] [Related]
9. In vitro modulation of tumor progression-associated properties of hormone refractory prostate carcinoma cell lines by cytokines.
Sokoloff MH; Tso CL; Kaboo R; Taneja S; Pang S; deKernion JB; Belldegrun AS
Cancer; 1996 May; 77(9):1862-72. PubMed ID: 8646686
[TBL] [Abstract][Full Text] [Related]
10. MHC class I-deficient metastatic tumor variants immunoselected by T lymphocytes originate from the coordinated downregulation of APM components.
Garcia-Lora A; Martinez M; Algarra I; Gaforio JJ; Garrido F
Int J Cancer; 2003 Sep; 106(4):521-527. PubMed ID: 12845647
[TBL] [Abstract][Full Text] [Related]
11. Resistance to lysis by cytotoxic T cells: a dominant effect in metastatic mouse prostate cancer cells.
Lee HM; Timme TL; Thompson TC
Cancer Res; 2000 Apr; 60(7):1927-33. PubMed ID: 10766182
[TBL] [Abstract][Full Text] [Related]
12. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy.
Restifo NP; Marincola FM; Kawakami Y; Taubenberger J; Yannelli JR; Rosenberg SA
J Natl Cancer Inst; 1996 Jan; 88(2):100-8. PubMed ID: 8537970
[TBL] [Abstract][Full Text] [Related]
13. Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer.
Korkolopoulou P; Kaklamanis L; Pezzella F; Harris AL; Gatter KC
Br J Cancer; 1996 Jan; 73(2):148-53. PubMed ID: 8546899
[TBL] [Abstract][Full Text] [Related]
14. A Flow Cytometry-Based Approach to Unravel Viral Interference with the MHC Class I Antigen Processing and Presentation Pathway.
Praest P; de Buhr H; Wiertz EJHJ
Methods Mol Biol; 2019; 1988():187-198. PubMed ID: 31147941
[TBL] [Abstract][Full Text] [Related]
15. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression.
Rowe M; Khanna R; Jacob CA; Argaet V; Kelly A; Powis S; Belich M; Croom-Carter D; Lee S; Burrows SR
Eur J Immunol; 1995 May; 25(5):1374-84. PubMed ID: 7774641
[TBL] [Abstract][Full Text] [Related]
16. IFN-γ treatment protocol for MHC-I
Stifter K; Krieger J; Ruths L; Gout J; Mulaw M; Lechel A; Kleger A; Seufferlein T; Wagner M; Schirmbeck R
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32868392
[TBL] [Abstract][Full Text] [Related]
17. Rescue of MHC-1 antigen processing machinery by down-regulation in expression of IGF-1 in human glioblastoma cells.
Pan Y; Trojan J; Guo Y; Anthony DD
PLoS One; 2013; 8(3):e58428. PubMed ID: 23526983
[TBL] [Abstract][Full Text] [Related]
18. IFN-gamma gene transfer restores HLA-class I expression and MAGE-3 antigen presentation to CTL in HLA-deficient small cell lung cancer.
Traversari C; Meazza R; Coppolecchia M; Basso S; Verrecchia A; van der Bruggen P; Ardizzoni A; Gaggero A; Ferrini S
Gene Ther; 1997 Oct; 4(10):1029-35. PubMed ID: 9415308
[TBL] [Abstract][Full Text] [Related]
19. Constitutive transduction of peptide transporter and HLA genes restores antigen processing function and cytotoxic T cell-mediated immune recognition of human melanoma cells.
White CA; Thomson SA; Cooper L; van Endert PM; Tampe R; Coupar B; Qiu L; Parsons PG; Moss DJ; Khanna R
Int J Cancer; 1998 Feb; 75(4):590-5. PubMed ID: 9466661
[TBL] [Abstract][Full Text] [Related]
20. Generation of CD8+ T cells specific for transporter associated with antigen processing deficient cells.
Wolpert EZ; Petersson M; Chambers BJ; Sandberg JK; Kiessling R; Ljunggren HG; Kärre K
Proc Natl Acad Sci U S A; 1997 Oct; 94(21):11496-501. PubMed ID: 9326638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
